Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia

Jo Ishizawa, Eiji Sugihara, Shinji Kuninaka, Kaoru Mogushi, Kensuke Kojima, Christopher B. Benton, Ran Zhao, Dhruv Chachad, Norisato Hashimoto, Rodrigo O. Jacamo, Yihua Qiu, Suk Young Yoo, Shinichiro Okamoto, Michael Andreeff, Steven M. Kornblau, Hideyuki Saya

Blood (2017) 129 (14): 1958–1968.

https://doi.org/10.1182/blood-2016-07-726216

Published: 2017

Includes: Supplemental data

Journal Articles

Development of a New Mouse Model for Mature B Cell Lymphoma and Resistance to Fas Restoration-Triggered Apoptosis

Eiji Sugihara, PhD, Norisato Hashimoto, MD, Satoru Osuka, MD PhD, Ueno Sayaka, MD, Shinichiro Okamoto, MD PhD, Hideyuki Saya, MD PhD

Blood (2016) 128 (22): 1757.

https://doi.org/10.1182/blood.V128.22.1757.1757

Published: 2016

Journal Articles

Chemo-Immunotherapy With Hyper-CVAD/MA and Rituximab For B-Cell Lymphomas Leads To Prolonged Immune Suppression Compared To Conventional Treatment With R-CHOP

Eri Matsuki, MD, PhD, Taku Kikuchi, MD, Norisato Hashimoto, MD, Shunsuke Souma, MD, Sumiko Kohashi, MD, Takaaki Toyama, MD, Masatoshi Sakurai, MD, Daiki Karigane, MD, Daichi Abe, MD, Takayuki Shimizu, MD, PhD, Kenji Yokoyama, MD, PhD, Hideaki Nakajima, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2013) 122 (21): 1800.

https://doi.org/10.1182/blood.V122.21.1800.1800

Published: 2013

Journal Articles

Loss of Function of The Cell Cycle Regulator Cdh1 Causes Cell Fragility due to Aberrant G2/M Checkpoint and Develops Resistant Disease in a B-ALL/LBL Mouse Model

Jo Ishizawa, MD, PhD, Eiji Sugihara, PhD, Norisato Hashimoto, MD, Shinji Kuninaka, MD, PhD, Kensuke Kojima, MD, PhD, Michael Andreeff, MD, PhD, Shinichiro Okamoto, MD, PhD, Hideyuki Saya, MD, PhD

Blood (2013) 122 (21): 344.

https://doi.org/10.1182/blood.V122.21.344.344

Published: 2013

Journal Articles

Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study.

Eri Matsuki, MD, PhD, Yukako Ono, MD, Koharu Tonegawa, Masatoshi Sakurai, MD, Hiroyoshi Kunimoto, MD, Jo Ishizawa, MD, PhD, Norisato Hashimoto, MD, Takayuki Shimizu, MD, PhD, Akiko Yamane, MD, PhD, Maiko Matsushita, MD, PhD, Kenji Yokoyama, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2012) 120 (21): 2788.

https://doi.org/10.1182/blood.V120.21.2788.2788

Published: 2012

Journal Articles

Role of the Cell Cycle Regulator Cdh1 in Physiology and Pathology of Hematopoiesis

Jo Ishizawa, MD, PhD, Eiji Sugihara, PhD, Norisato Hashimoto, MD, Shinji Kuninaka, MD, PhD, Shinichiro Okamoto, MD, PhD, Hideyuki Saya, MD, PhD

Blood (2011) 118 (21): 2419.

https://doi.org/10.1182/blood.V118.21.2419.2419

Published: 2011

NARROW

FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia

Development of a New Mouse Model for Mature B Cell Lymphoma and Resistance to Fas Restoration-Triggered Apoptosis

Chemo-Immunotherapy With Hyper-CVAD/MA and Rituximab For B-Cell Lymphomas Leads To Prolonged Immune Suppression Compared To Conventional Treatment With R-CHOP

Loss of Function of The Cell Cycle Regulator Cdh1 Causes Cell Fragility due to Aberrant G2/M Checkpoint and Develops Resistant Disease in a B-ALL/LBL Mouse Model

Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study.

Role of the Cell Cycle Regulator Cdh1 in Physiology and Pathology of Hematopoiesis

Email alerts

ASH Publications

American Society of Hematology

FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia

Development of a New Mouse Model for Mature B Cell Lymphoma and Resistance to Fas Restoration-Triggered Apoptosis

Chemo-Immunotherapy With Hyper-CVAD/MA and Rituximab For B-Cell Lymphomas Leads To Prolonged Immune Suppression Compared To Conventional Treatment With R-CHOP

Loss of Function of The Cell Cycle Regulator Cdh1 Causes Cell Fragility due to Aberrant G2/M Checkpoint and Develops Resistant Disease in a B-ALL/LBL Mouse Model

Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study.

Role of the Cell Cycle Regulator Cdh1 in Physiology and Pathology of Hematopoiesis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only